Blood-based PhenoAge may reflect disease burden rather than biological aging in cancer
In the authors' words
PhenoAge, a blood-based biological aging clock, is associated with cancer outcomes, a finding taken as evidence that biological aging shapes prognosis. In 3,067 patients undergoing primary tumor resection, PhenoAge acceleration rose with tumor stage. One or two of its eight blood components, differing by cancer type, carried the prognostic signal, and replacing its general-population weights with equal weights did not weaken it. In cancer, PhenoAge may reflect disease burden rather than biological aging.
Main resultThe abstract does not state a limitation.
Appeared: Tuesday, October 20. medRxiv. Preprint, not yet peer-reviewed.